An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab in Patients With Advanced Gastric Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 31 Jul 2019 Planned End Date changed from 31 Dec 2021 to 31 Mar 2022.
- 31 Jul 2019 Planned primary completion date changed from 30 Jun 2020 to 25 Sep 2019.
- 31 Jul 2019 Status changed from recruiting to active, no longer recruiting.